Amino acid sequence for inhibiting ptx3 to treat nasopharyngeal carcinoma

Abstract

The invention relates to an amino acid sequence for inhibiting PTX3 to treat nasopharyngeal carcinoma. It can be used to inhibit PTX3 from promoting the migration and invasion of nasopharyngeal carcinoma cells, promoting angiogenesis and inhibiting macrophage phagocytosis to further treat nasopharyngeal carcinoma.

What is claimed is: 
     
         1 . An amino acid sequence for inhibiting PTX3 to treat nasopharyngeal carcinoma, comprising at least 85% sequence homology with SEQ ID NO:1, is used to inhibit PTX3 from promoting the migration and invasion of nasopharyngeal carcinoma cells, promoting angiogenesis and inhibiting macrophage phagocytosis. 
     
     
         2 . The amino acid sequence for inhibiting PTX3 to treat nasopharyngeal carcinoma as claimed in  claim 1 , wherein the amino acid sequence comprises at least 90% sequence homology with SEQ ID NO:1. 
     
     
         3 . The amino acid sequence for inhibiting PTX3 to treat nasopharyngeal carcinoma as claimed in  claim 2 , wherein the amino acid sequence comprises at least 95% sequence homology with SEQ ID NO:1. 
     
     
         4 . The amino acid sequence for inhibiting PTX3 to treat nasopharyngeal carcinoma as claimed in  claim 3 , wherein the amino acid sequence is SEQ ID NO:1. 
     
     
         5 . A pharmaceutical composition for treating nasopharyngeal carcinoma in mammals, comprises therapeutically effective dosage of amino acid sequence as claimed in  claim 1  in treatment, and one or more acceptable carriers in medicine. 
     
     
         6 . The pharmaceutical composition as claimed in  claim 5 , wherein the carrier is selected from the group consisting of excipient, diluent, thickener, filler, binder, disintegration agent, lubricant, sebum or non-sebum base agent, surfactant, suspending agent, gelling agent, auxiliary agent, preservative, antioxidant, stabilizing agent, colorant and flavoring. 
     
     
         7 . The pharmaceutical composition as claimed in  claim 5 , wherein the pharmaceutical composition is used to manufacture drugs for treating nasopharyngeal carcinoma. 
     
     
         8 . The pharmaceutical composition as claimed in  claim 5 , wherein the mammal is a human patient. 
     
     
         9 . The pharmaceutical composition as claimed in  claim 8 , wherein the pharmaceutical composition is administered to a human patient by means of oral administration, injection, daub or patch. 
     
     
         10 . A nuclear acid sequence is translated to an amino acid sequence set forth in SEQ ID NO:1.